Publications by authors named "Chunlu Gao"
Article Synopsis
- The study examines how much arsenic species bind to proteins in patients with acute promyelocytic leukemia, noting that this binding varies with liver or kidney function.
- Blood samples were taken from APL patients with normal and impaired liver or kidney function to measure the percentage protein binding of various arsenic species using advanced testing methods.
- Results showed that patients with normal kidney function have specific binding percentages for different arsenic species, with significant decreases in binding for those with kidney impairment, while liver function did not significantly affect binding levels.
Arsenic trioxide (AsO) has prominent effect in treating acute promyelocytic leukemia (APL). Identification of arsenic-binding proteins has gained attention for their important biological functions. However, none has been published concerning the binding mechanism of arsenic with hemoglobin (Hb) in APL patients after treatment of AsO.
View Article and Find Full Text PDFWhat Is Known And Objectives: The aim of this study was to investigate the pharmacokinetics (PK) of cefoperazone (CFP) and sulbactam (SUL) in critically ill thrombotic thrombocytopenic purpura (TTP) patients undergoing therapeutic plasma exchange (TPE).
Methods: Critically ill TTP patients receiving a dose of 3 g CFP/SUL (2.0 g/1.
Article Synopsis
- Arsenic trioxide (ATO) is used to treat acute promyelocytic leukemia (APL), and this study examines the different arsenic species present in red blood cells and their impact on toxicity and treatment efficacy.
- Blood samples from 97 APL patients were analyzed for arsenic species using a method involving hemoglobin release, protein precipitation, and High-Performance Liquid Chromatography with Hydride Generation Atomic Fluorescence Spectrometry (HPLC-HG-AFS).
- The research found that inorganic arsenic (iAs) was more prevalent in RBCs compared to other forms, while dimethylarsinic acid (DMA) was most abundant in plasma; MMA had high binding affinity to hemoglobin, explaining arsenic
Arsenic trioxide [AsO, arsenite (As) in solution] has been applied successfully for the treatment of acute promyelocytic leukemia (APL). The arsenic speciation analysis of urine is critical to reveal the metabolic mechanism and the relationship between arsenic species and the clinical response. To characterize the arsenic species in urine, a simple and robust HPLC-HG-AFS method was developed and validated to quantify the levels of arsenic species [As and its metabolites, monomethylarsonic acid (MMA), dimethylarsinic acid (DMA), and arsenate (As)] in urine samples from 66 patients with APL.
View Article and Find Full Text PDFArticle Synopsis
- Arsenic trioxide (ATO) is commonly used to treat acute promyelocytic leukemia (APL), and a study was conducted to investigate its metabolism and toxicity in the red blood cells (RBCs) of APL patients.
- Nine APL patients received ATO through an 18-hour infusion, and blood samples were collected for analysis, revealing that inorganic arsenic (iAs) and its metabolites accumulated steadily in the RBCs during the treatment period.
- The findings highlighted that iAs was the most prevalent arsenic species in RBCs, with monomethylarsonic acid (MMA) being the dominant metabolite; importantly, the concentrations of these species were significantly higher in
This study presents outcome and pharmacokinetics of arsenic trioxide (ATO) metabolites in patients on continuous venovenous haemodialysis (CVVHD). Of 3 acute promyelocytic leukaemia patients receiving CVVHD in management of acute kidney injury, only 1 patient was included. The patient presented disseminated intravascular coagulation and acute kidney injury before induction therapy was conducted.
View Article and Find Full Text PDFPurpose: This study evaluated pharmacokinetics (PK) and safety profiles of single agent arsenic trioxide (ATO, AsO) administrated as continuous slow-rate infusion in patients with newly diagnosed acute promyelocytic leukemia.
Patients And Methods: Patients received 0.16 mg/kg ATO per day.
Hydroxyurea (HU) has been used in the treatment of chronic myeloid leukaemia (CML) and other myeloproliferative malignancies. Considering patient's wide variation in clinical response to HU, a new and simple liquid chromatography-tandem mass spectrometry (LC-MS/MS) method was developed and validated to monitor patients' compliance to treatment and investigate the pharmacokinetics of HU in patients with CML. Stable isotope labeled HU-C,N was used as internal standard.
View Article and Find Full Text PDFArticle Synopsis
- Cefoperazone/sulbactam (CFP/SUL) pharmacokinetics were studied in critically ill patients on continuous venovenous hemofiltration (CVVH) to develop dosing guidelines.
- Fourteen patients participated in the study, showing significantly altered volume distribution and lower total clearance of both drugs compared to healthy individuals.
- Therapeutic drug monitoring is recommended due to these PK changes, with most patients achieving the target concentrations needed for effective treatment.